Mental health professionals have been exploring psychedelics as a treatment for substance abuse and mental health disorders for decades, and now its status as a legitimate treatment is being recognized in Canada.
Exploring the companies and themes that make up this emerging and exciting new sector
Awakn Life Sciences Receives Bold Price Target From H.C. Wainwright
This morning, Awakn Life Sciences Corp. became the latest psychedelic company to obtain coverage under the H.C. Wainwright umbrella.
Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?
As new deep pockets emerge to finance psychedelic drug development, we also learn that this R&D isn't as expensive as some drug companies claim.
Psychedelic Medicine Blazing New Trails: A Q&A With CEO Anthony Tennyson and Dr. Celia Morgan
Beyond substance abuse, behavioral addictions are also a major problem in society. We went to addiction-specialist, Awakn Life Sciences to learn more these additional treatment markets.
Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions
Awakn files a patent application in support of a new class of molecules for the treatment of addiction.
MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022
MINDCURE reports its Q2 fiscal 2022 results. The Company recorded a loss of CAD$2.95 million. Its cash position is now CAD$13.4 million.
FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder
Mindmed receives IND clearance from the FDA for MM-120, paving the way for its Phase IIb clinical trial for generalized anxiety disorder.
Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans
Mydecine announces a partnership with Combat Stress and King's College London to provide psychoactive-assisted therapy for PTSD.
Novamind Announces CAD$5 Million Private Placement with Institutional Investor
Novamind announces a CAD$5 million placement with a single institutional investor. Units are priced at CAD$0.40 with a full warrant at CAD$0.50.
Momentum Building For U.S. Psychedelics Legal Reform
Sudden indications of a regulatory thaw in the U.S. toward psychedelic medicine bode well for psychedelic stocks in 2022.
Numinus Wellness Inc. Reports Q1 2022 Results
Numinus Wellness reports Q1 2022 results, including quarterly revenues of CAD$0.8 million and a gross profit of CAD$50,965.
Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II
Eleusis, a private psychedelics company, has announced it is going public via a merger with Silver Spike Acquisition Corp II.